In vivo intra-uterine delivery of TAT-fused Cre recombinase and CRISPR/Cas9 editing unveil histopathology of Pten/p53-deficient endometrial cancers. https://www.biorxiv.org/content/10.1101/2023.06.08.544224v1?med=mas
In vivo intra-uterine delivery of TAT-fused Cre recombinase and CRISPR/Cas9 editing unveil histopathology of Pten/p53-deficient endometrial cancers. https://www.biorxiv.org/content/10.1101/2023.06.08.544224v1?med=mas